Tenax Therapeutics Amends Executive Severance, Adopts New Change-in-Control and Severance Plans
TENX has more than doubled off its 52-week low of $5.66.
Summary
Tenax Therapeutics updated executive employment agreements to include enhanced severance and change-in-control benefits, and established new company-wide plans for other employees.
Key Events · Executive and Board Changes · TENX
-
Executive Employment Agreement Amendments
The employment agreements for CEO Christopher Giordano, CFO Thomas Staab, and CMO Stuart Rich were amended to provide enhanced severance and change-in-control benefits. For terminations not related to a change in control, executives are entitled to 12-24 months of base salary, a pro-rated annual bonus, and 12 months of COBRA. For terminations related to a change in control, benefits include 12-18 months of base salary, 100% annual bonus, accelerated equity vesting, and 12-18 months of COBRA.
-
New Change in Control Plan Adopted
The Board adopted a new Change in Control (CIC) Plan for eligible employees (excluding executive officers). This plan provides 'double trigger' equity acceleration and cash severance benefits upon a qualifying termination occurring around a change in control transaction.
-
New Severance Plan Adopted
A new Severance Plan was adopted for eligible employees (excluding executive officers), providing severance benefits upon termination by the company without cause, independent of a change in control transaction.
Analysis · TENX · Life Sciences
The company formalized enhanced severance and change-in-control benefits for its CEO, CFO, and CMO through amendments to their employment agreements. Additionally, new Change in Control and Severance Plans were adopted for other eligible employees. These actions aim to provide clarity on executive compensation in various termination scenarios and serve as a retention mechanism for key talent.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TENX was trading at $13.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $358.1M. The 52-week trading range was $5.66 to $18.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.